Related references
Note: Only part of the references are listed.Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Boris Bikbov et al.
LANCET (2020)
Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review
John A. Glaspy et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2020)
Targeting the progression of chronic kidney disease
Marta Ruiz-Ortega et al.
NATURE REVIEWS NEPHROLOGY (2020)
Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses
Geoffrey A. Block et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD
Geoffrey A. Block et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Differential Impacts of Intravenous Iron Administration and Iron-Containing Phosphate Binders on Serum Intact Fibroblast Growth Factor 23 Levels
Hirokazu Honda et al.
BLOOD PURIFICATION (2019)
Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoietin Responsiveness in Hemodialysis Patients
Noriaki Maruyama et al.
AMERICAN JOURNAL OF NEPHROLOGY (2018)
Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency
Akira Iguchi et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2018)
Parenteral iron polymaltose changes i:c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients
S-J Tan et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2017)
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
Adeera Levin et al.
LANCET (2017)
Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production
Valentin David et al.
KIDNEY INTERNATIONAL (2016)
A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients With CKD Stages 3-5
Geoffrey A. Block et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
Ferric Citrate Hydrate for the Treatment of Hyperphosphatemia in Nondialysis-Dependent CKD
Keitaro Yokoyama et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Hypophosphatemic Rickets: Revealing Novel Control Points for Phosphate Homeostasis
Kenneth E. White et al.
CURRENT OSTEOPOROSIS REPORTS (2014)
Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women
Myles Wolf et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Extending DerSimonian and Laird's methodology to perform multivariate random effects meta-analyses
Dan Jackson et al.
STATISTICS IN MEDICINE (2010)
FGF23 Elevation and Hypophosphatemia after Intravenous Iron Polymaltose: A Prospective Study
Belinda J. Schouten et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)